Health
US Allows More Vyvanse Production to Address ADHD Drug Shortages
This article is for subscribers only.
US drug authorities are allowing 24% more production of Vyvanse, an ADHD drug from Takeda Pharmaceutical Co. and generic rivals, to address treatment shortages that have dragged on for the past two years.
Medicines for attention-deficit/hyperactivity disorder have been in short supply since the summer of 2022, when labor issues curtailed availability of Adderall — a cornerstone of treatment — amid increasing demand. Patients turned to alternative therapies, leading to knock-on shortages of drugs including Vyvanse.